Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
1,608
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of LungLB for the clinical management of patients with indeterminate pulmonary nodules

John E. Schneidera Health Economics & Outcomes Research (HEOR), Avalon Health Economics LLC, Morrristown, NJ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1878-8118View further author information
ORCID Icon,
Shawn Daviesa Health Economics & Outcomes Research (HEOR), Avalon Health Economics LLC, Morrristown, NJ, USAView further author information
,
Maggie Do Vallea Health Economics & Outcomes Research (HEOR), Avalon Health Economics LLC, Morrristown, NJ, USAView further author information
,
Nadine Chamia Health Economics & Outcomes Research (HEOR), Avalon Health Economics LLC, Morrristown, NJ, USAORCID Iconhttps://orcid.org/0000-0002-8620-085XView further author information
ORCID Icon,
Paul C. Paganob LungLife AI, Thousand Oaks, CA, USAView further author information
,
David Andersonb LungLife AI, Thousand Oaks, CA, USAView further author information
&
Michael J. Donovanb LungLife AI, Thousand Oaks, CA, USA;c Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
 show all
Pages 342-347 | Received 29 Dec 2022, Accepted 15 Feb 2023, Published online: 03 Mar 2023

References

  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
  • Noone AM, Howlader N, Krapcho M, editors, et al. SEER cancer statistics review, 1975–2015. Bethesda (MD): National Cancer Institute.
  • de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. New Eng J Med. 2020;382(6):503–513.
  • Paez R, Kammer MN, Massion P. Risk stratification of indeterminate pulmonary nodules. Curr Opin Pulm Med. 2021;27(4):240–248.
  • Pyenson BS, Bazell CM, Bellanich MJ, et al. No apparent workup for most new indeterminate pulmonary nodules in US commercially-insured patients. J Health Econ Outcomes Res. 2019;6(3):118–129.
  • Vachani A, Tanner NT, Aggarwal J, et al. Factors that influence physician decision making for indeterminate pulmonary nodules. Ann Am Thorac Soc. 2014;11(10):1586–1591.
  • Detterbeck FC, Lewis SZ, Diekemper R, et al. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2013;143(5):7S–37S.
  • Rickets W, Lau KKW, Pollit V, et al. Exploratory cost-effectiveness model of electromagnetic navigation bronchoscopy (ENB) compared with CT-guided biopsy (TTNA) for diagnosis of malignant indeterminate peripheral pulmonary nodules. BMJ Open Respir Res. 2020;7(1):e000595.
  • Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003;138(9):724–735.
  • Maiga AW, Deppen SA, Mercaldo SF, et al. Assessment of fluorodeoxyglucose F18-labeled positron emission tomography for diagnosis of high-risk lung nodules. JAMA Surg. 2018;153(4):329–334.
  • Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules: application to small radiologically indeterminate nodules. Arch Intern Med. 1997;157(8):849–855.
  • Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: one-year results of the prospective, multicenter NAVIGATE study. J Thorac Oncol. 2019;14(3):445–458.
  • Yang B, Jhun BW, Shin SH, et al. Comparison of four models predicting the malignancy of pulmonary nodules: a single-center study of Korean adults. PLoS One. 2018;13(7):e0201242.
  • Huo J, Xu Y, Sheu T, et al. Complication rates and downstream medical costs associated with invasive diagnostic procedures for lung abnormalities in the community setting. JAMA Internal Med. 2019;179(3):324–332.
  • Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States veterans affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003;181(2):359–365.
  • Services, C.f.M.M. Physician fee schedule. 2016.
  • Sheehan DF, Criss SD, Chen Y, et al. Lung cancer costs by treatment strategy and phase of care among patients enrolled in medicare. Cancer Med. 2019;8(1):94–103.
  • Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–816.
  • Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach. Lung Cancer. 2018;124:189–198.
  • Life table for the total population: United States, 2017–2021. Available from: https://www.cdc.gov/nchs/nvss/life-expectancy.htm
  • Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ. 2014;10:1289–1301.
  • Englmeier F, Bleckmann A, Brückl W, et al. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. 2022. DOI:10.1007/s00432-022-04034-w
  • Li W, Liu JB, Hou LK, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21:25.
  • Tan AC. The role of liquid biopsy in the diagnostic testing algorithm for advanced lung cancer. Onco. 2022;2:181–185.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.